Abnormal amplification of centrosomes, commonly found in human cancer, is the major cause of mitotic defects and chromosome instability in cancer cells. Like DNA, centrosomes duplicate once in each cell cycle, hence the defect in the mechanism that ensures centrosome duplication to occur once and only once in each cell cycle results in abnormal amplification of centrosomes and mitotic defects. Centrosomes are non-membranous organelles, and undergo dynamic changes in its constituents during the centrosome duplication cycle. Through a comparative mass spectrometric analysis of unduplicated and duplicated centrosomes, we identified mortalin, a member of heat shock protein family, as a protein that associates preferentially with duplicated centrosomes. Further analysis revealed that mortalin localized to centrosomes in late G1 before centrosome duplication, remained at centrosomes during S and G2, and dissociated from centrosomes during mitosis. Overexpression of mortalin overrides the p53-dependent suppression of centrosome duplication, and mortalin-driven centrosome duplication requires physical interaction between mortalin and p53. Moreover, mortalin promotes dissociation of p53 from centrosomes through physical interaction. The p53 mutant that lacks the ability to bind to mortalin remains at centrosomes, and suppresses centrosome duplication in a transactivation function-independent manner. Thus, our present findings not only identify mortalin as an upstream molecule of p53 but also provide evidence for the involvement of centrosomally localized p53 in the regulation of centrosome duplication.
Introduction
The centrosome is a major microtubule organizing center of an animal cell, and plays a critical role in bipolar spindle formation during mitosis, which is essential for accurate chromosome segregation during cytokinesis. The centrosome is composed of a pair of centrioles and a surrounding protein aggregates referred to as pericentriolar material (Lange and Gull, 1996) . Like DNA, centrosomes duplicate once in each cell cycle, which normally starts at the time of S-phase entry and is completed in late G2-phase (Hinchcliffe and Sluder, 2002) . Centrosome duplication occurs in a highly regulated manner, and abrogation of this regulation results in multiple rounds of centrosome duplication within a single cell cycle, generating more than two centrosomes (centrosome amplification), which in turn increases the frequencies of mitotic defect and unbalanced chromosome segregation. Indeed, centrosome amplification is frequently found in cancer cells, and occurrence of centrosome amplification is strongly associated with chromosome instability (D'Assoro et al., 2002; Fukasawa, 2005) .
The centrosome is a non-membranous organelle, making a number of proteins rather freely access to this organelle. Indeed, the constituents of centrosomes change dynamically during the cell and centrosome cycles, involving many different proteins, some of which are permanent constituents of centrosomes, whereas some localize at centrosomes in a cell and centrosome duplication cycle-dependent manner. The latter includes many of the proteins that control centrosome duplication. Thus, it is reasonable to predict that the centrosomal components of unduplicated and duplicated centrosomes critically differ. Here, we comparatively analysed centrosomal proteins of unduplicated and duplicated centrosomes. We found that mortalin (also known as mot-2, Grp75, PBP-74, mtHsp70), a member of hsp70 family, was one of the proteins that preferentially associate with duplicated centrosomes. Mortalin was initially identified as the protein that differs in the subcellular localization in normal and transformed mouse and human cells (Wadhwa et al., 1993 (Wadhwa et al., , 1995 . In normal cells, mortalin is uniformly distributed in the cytoplasm, whereas in transformed cells it is concentrated in the perinuclear region. Mortalin has also been shown to localize to the mitochondria as well as endoplasmic reticulum (Ran et al., 2000) . Mortalin is expressed in all cell types and tissues, and possesses diverse activities, including oncogenic transformation, lifespan extension, attenuation of differentiation, molecular chaperone, radioresistance, antigen processing and T-cell recognition (reviewed by Kaul et al., 2002) . Mortalin has also been shown to directly bind p53 tumor suppressor protein, and at least some of the phenotypes and biological events associated with mortalin are believed to be attributed to its physical association with p53 (Wadhwa et al., 1998 .
Here, we explored the centrosomal localization and role of mortalin in the regulation of centrosome duplication. We found that mortalin starts to localize to unduplicated centrosomes at late G1 phase, remains at duplicated centrosomes until mitosis where it dissociates from centrosomes. We further found that overexpression of mortalin drives centrosome duplication, and overrides the p53-dependent suppression of centrosome re-duplication in cells arrested by DNA synthesis inhibitors. The physical interaction between mortalin and p53 in cells used in this study appears to affect neither the transactivation function nor protein stability of p53, but rather affect the centrosomal localization of p53. Through binding to mortalin, p53 loses the affinity to centrosomes, promoting its dissociation from centrosomes, which in turn results in releasing the p53-dependent suppression of centrosome duplication. Thus, our present study identifies mortalin as one of centrosome-associating proteins that acts on p53 in the regulation of centrosome duplication, and provides the evidence for the transactivation function-independent regulation of centrosome duplication by p53 localized at centrosomes.
Results

Characterization of centrosomal localization of mortalin
Many proteins involved in the regulation of centrosome duplication are known to localize at centrosomes in the centrosome duplication cycle-dependent manner. Thus, unduplicated and duplicated centrosomes are expected to be substantially different in their constituents. On this premise, we performed a comparative proteomics analysis of the unduplicated and duplicated centrosomes. We used a HeLa1 human cell line, a clonal derivative of HeLa cervical cancer cells. Unlike the parental HeLa cells, HeLa1 cells show a serumdependent growth and a centrosome profile similar to normal cells, and are equipped with the p53-dependent centrosome duplication checkpoint (see Figure 1 ). In addition, although the parental HeLa cells are known to harbor human papillomavirus, expression of virally encoded protein E6 that promotes degradation of p53 (Scheffner et al., 1990) appears to be transcriptionally silenced in HeLa1 cells, and thus HeLa1 cells contain functionally intact p53 at a level similar to normal human cells. Under a normal growth condition, B70% of HeLa1 cells contained unduplicated (one) centrosomes, B29% duplicated (two) centrosomes and B1% amplified (X3) centrosomes ( Figure 1A , graph a; Figure 1B , panel a). Thus, asynchronously growing HeLa1 cells can be an appropriate source for isolating unduplicated centrosomes. It has been shown that when exposed to DNA synthesis, inhibitors such as hydroxyurea (HU; an inhibitor of ribonucleotide reductase (Timson, 1975) ), majority of the unduplicated centrosomes complete duplication, yet further duplication (re-duplication) of duplicated centrosomes is suppressed in the presence of p53 (Tarapore and Fukasawa, 2002) . Because HeLa1 cells contain functional p53, most unduplicated centrosomes complete duplication, but further duplication is suppressed during HU-induced arrest. For instance, when exposed to HU for 60 h, B70% of HeLa1 cells contain duplicated centrosomes, but only B10% contain amplified centrosomes ( Figure 1A , graph b; Figure 1B , panel b). Thus, HeLa1 cells exposed to HU for 60 h can be an appropriate source for isolating duplicated centrosomes. We isolated centrosomes from the asynchronously growing and HUtreated HeLa1 cells by discontinuous sucrose gradient fractionation. The fractions enriched for centrosomes were identified by immunoblot analysis for g-tubulin, a protein found at centrosomes throughout the cell cycle (Oakley, 2000) . The g-tubulin was present at the highest level in fraction 6 for the unduplicated centrosomes, and in the fraction 5 for the duplicated centrosomes ( Figure 1C(a and b) ). Equal amounts of the isolated unduplicated and duplicated centrosomes were subject to two-dimensional (2D) gel electrophoresis ( Figure 1D , a and b). The overall 2D spot patterns of the isolated centrosomes were similar to those previously published for the highly enriched centrosomes . However, there were spots clearly different between unduplicated and duplicated centrosomes, some of which showed readily recognizable changes in the spot intensity, some were specific to unduplicated centrosomes, and some were specific to duplicated centrosomes. In some, 49 spots were found as common spots, 23 spots unduplicated centrosome specific (either higher intensity or unique) spot and 43 spots duplicated centrosome-specific. It should be noted that these spots do not necessarily represent different proteins, but some spots represent the same protein with different post-translational modifications.
The spots specific to either unduplicated or duplicated centrosomes were excised and subject to mass spectrometric analysis. Of these spots analysed, we identified one spot as mortalin, a member of the Hsp70 family of proteins ( Figure 1D , indicated by arrows). The mortalin spot is present at a high level in the duplicated centrosomes, whereas at a greatly reduced level in the unduplicated centrosomes (see magnified images in the insets in Figure 1D ).
To confirm the centrosomal association of mortalin, we first immunoblotted the sucrose gradient fractions from asynchronous and HU-treated HeLa-1 cells with anti-g-tubulin as well as anti-mortalin antibody ( Figure 2A) . Mortalin was present at a high level in the duplicated centrosome fraction (Figure 2A(b) , fraction 5), whereas at a significantly reduced level in the unduplicated centrosome fraction (Figure 2A(a) , fraction 6). As mortalin has also been found in the mitochondria (Ran et al., 2000) , we tested whether the centrosome fractions were contaminated with the mitochondria by immunoblotting for Bcl-xL, a known mitochondrial protein (Tsujimoto, 1998) (Figure 2A  (a and b) , bottom panel). No Bcl-xL signal was detected Asynchronously growing HeLa1 cells as well as HeLa1 cells exposed to hydroxyurea (HU) for 60 h were immunostained with anti-g-tubulin (centrosomes, green), and counterstained for DNA with 4 0 ,6 0 -diamidino-2-phenylindole (blue). The number of centrosomes per cell was scored, and shown in graphs in (A). The representative immunostaining images are shown in (B). Scale bar, 10 mm. (C) Cytoplasmic extracts prepared from asynchronously growing (a) and HU-treated HeLa1 cells (b) were subjected to sucrose gradient centrifugation, and the fractions collected from bottom of the tubes were immunoblotted with anti-g-tubulin antibody to identify the fractions enriched for centrosomes. (D) The fractions enriched for unduplicated and duplicated centrosomes (fraction 6 of asynchronously growing cells (a) and fraction 5 of HU-treated cells (b), respectively) were resolved by two-dimensional-gel electrophoresis. One of the spots with increased levels in duplicated centrosomes compared with unduplicated centrosomes (indicated by arrows, magnified images of the indicated areas are shown in the insets) was identified to be mortalin by mass spectrometric analysis. The cytoplasmic extracts prepared from asynchronously growing (a) and hydroxyurea-treated HeLa1 cells (b) were fractionated by the sucrose gradient centrifugations, and the fractions were immunoblotted with anti-mortalin (top panels), anti-g-tubulin (middle panels) and anti-Bcl-xL (bottom panels) antibodies. The extracts (1%) before sucrose gradient centrifugation were included in the analysis as a reference (denoted as C). (B) Asynchronously growing HeLa1 cells were co-immunostained for g-tubulin (panels a, e, i, green) and mortalin (panels b, f, j, red). Cells were also stained for DNA with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI) (panels c, g, k, blue). Panels d, h and l show the superimposed images. Panels a-h show the cells with an unduplicated centrosome, and panels i-l show the cells with duplicated centrosomes. Arrows point to the positions of centrosomes. The images placed on the right show the magnified images of the areas indicated by arrows. Scale bar, 10 mm. Among unduplicated and duplicated centrosomes, the frequencies of centrosomal localization of mortalin (colocalization of mortalin and g-tubulin) were determined, and plotted in the graph (C). (D) HeLa1 cells in parallel cultures were synchronized by serum starvation for 24 h, followed by serum stimulation. 5-Bromodeoxyridine (BrdU) was added to media in one culture during serum stimulation. At indicated time point after serum stimulation, cells were fixed, and either immunostained with anti-BrdU antibody for determining the rate of BrdU incorporation (a) or co-immunostained with anti-g-tubulin and anti-mortalin antibodies for determining the centrosomal localization of mortalin (b). (E) HeLa1 cells were co-immunostained for g-tubulin (panels a and e, green) and mortalin (panels b and f, red). Cells were also stained for DNA with DAPI (panels c and g, blue). Panels d and h show the superimposed images. Panels a-d show a metaphase cell, and panels e-h show a telophase/cytokinetic cell. Arrows point to the positions of centrosomes. Scale bar, 10 mm.
in the fractions enriched for centrosomes, excluding the possibility of mitochondrial contamination.
We next immunocytochemically examined centrosomal association of mortalin. Asynchronously growing HeLa1 cells were briefly extracted, fixed and coimmunostained for g-tubulin and mortalin ( Figure 2B ). Mortalin was found at >90% of duplicated centrosomes ( Figure 2B , panels i-l, Figure 2C ). However, mortalin was absent at the majority of unduplicated centrosomes (B70%, Figure 2B , panels a-d, Figure 2C ), and was found at only B30% of unduplicated centrosomes ( Figure 2B panels e-h, Figure 2C ). The finding that only minor population of unduplicated centrosomes are bound by mortalin strongly suggests that mortalin may associate with unduplicated centrosomes in a cell cycle-dependent manner, especially during G1 progression, as centrosome duplication initiates at late G1 to early S-phase. To obtain an insight, we synchronized HeLa1 cells by serum-starvation followed by serum-stimulation, and determined the cell cycle progression (by measuring the rate of BrdU incorporation, Figure 2D (a)) and the kinetics of mortalin localization to unduplicated centrosomes (by coimmunostaining with anti-mortalin and anti-g-tubulin antibodies, Figure 2D(b) ). The kinetics of mortalin localization to unduplicated centrosomes parallels to the rate of BrdU incorporation, indicating that mortalin associates with centrosomes during G1 before duplication. Examination of mitotic cells revealed that mortalin was only barely detectable at the spindle poles during metaphase ( Figure 2E , panels a-d), and no longer detectable during telophase (panels e-h), indicating that mortalin dissociates from centrosomes during mitosis. As mortalin is present in cells at similar levels throughout the cell cycle, the cell cycle (centrosome cycle) stage-specific centrosomal localization of mortalin is not owing to the changes in the overall mortalin levels. We also tested centrosomal localization of mortalin in other human cell lines such as U2OS and HEL299 cells, and found that mortalin localized to centrosomes in these cells in a similar manner (kinetics) to that of HeLa1 cells (data not shown). Thus, the cell cycledependent centrosomal localization of mortalin is not cell-type specific, but rather a general phenomenon. Taken together, mortalin is a centrosomal component with unique centrosomal association kinetics; it associates with centrosomes during G1 before duplication, remains associated with duplicated centrosomes during S and G2 and dissociates from centrosomes during mitosis.
Mortalin overexpression overrides the p53-dependent suppression of centrosome duplication As described earlier, when cells were exposed to DNA synthesis inhibitor (i.e., HU), cells complete centrosome duplication, but re-duplication of the duplicated centrosomes is suppressed in a p53-dependent manner. In the absence of p53, centrosomes continue to re-duplicate in the HU-arrested cells, resulting in the generation of amplified (X3) centrosomes. For instance, in HeLa1 cells silenced for p53 expression (>95% reduction) by small interfering RNA specific for p53 (Brummelkamp et al., 2002) (Figure 3A ), centrosomes continue to reduplicate during HU-induced arrest, resulting in the increased frequency of cells with amplified centrosomes ( Figure 3B ). It has previously been shown that mortalin negatively controls p53 function through direct binding (Wadhwa et al., 1998) . Together with our finding that mortalin localizes to centrosomes in a centrosome duplication cycle-dependent manner, we hypothesized that mortalin might play a role in the regulation of centrosome duplication. To this end, we examined whether forced expression of mortalin affects the ability to re-duplicate centrosomes during HU-induced arrest in HeLa1 cells. Green fluorescent protein (GFP)-tagged mortalin was transiently transfected into HeLa1 cells. As a control, GFP vector was transfected. We first tested whether the addition of the GFP-moiety would alter the centrosome-binding activity of the mortalin. The transfected cells at 36 h post-transfection were immunostained with anti-g-tubulin antibody. The GFP-moiety itself was not found at centrosomes ( Figure 3C , panels a-c). We found that GFP-mortalin localized to centrosomes in a manner similar to endogenous mortalin (representative immunostaining images are shown in Figure 3C , panels d-i). The transfectants were then exposed to HU for 72 h, immunostained for centrosomes, and the number of centrosomes per cell were determined ( Figure 3D ). In the GFP-vector-transfected cells, there was a small increase in the number of cells with X3 centrosomes after HU treatment (B10%) (representative immunostaining images are shown in Figure 3E , panels a and b). In contrast, in the GFP-mortalin-transfected cells, there was a marked increase in the number of cells with X3 centrosomes (B40%) (representative immunostaining images are shown in Figure 3E , panels c and d), indicating that many centrosomes have re-duplicated in the GFP-mortalin-transfected cells during HU-induced arrest. Thus, mortalin overexpression can override the p53-dependent suppression of centrosome re-duplication during HU-induced arrest, and drive centrosome duplication.
p53 binding is critical for mortalin to drive centrosome duplication It has been shown that mortalin physically interacts with p53, leading to cytoplasmic sequestration of p53 . The p53-binding sequence of mortalin has been mapped to amino acids (a.a.) 253-282 (Kaul et al., 2001) . We first tested whether mortalin and p53 physically interacts in HeLa1 cells. The lysates prepared from HeLa1 cells were immunoprecipitated using either anti-p53 antibody or control mouse IgG, and the immunoprecipitates were immunoblotted with anti-mortalin antibody ( Figure 4A(a) ). The anti-p53 antibody co-immunoprecipitated mortalin, confirming the complex formation between mortalin and p53 in HeLa1 cells. We next constructed plasmids encoding GFP-tagged wild-type (wt) mortalin and the mutant mortalin deleted for the p53-binding region (a.a. 253-282) (GFP-mortalinDp53BD). Green fluorescent protein-wt mortalin and GFP-mortalinDp53BD were transiently transfected into HeLa1 cells. As controls, GFP-vector was transfected. The transfectants were first examined for the p53-binding activities of GFP-wt mortalin and GFP-mortalinDp53BD by the co-immunoprecipitation assay. The immunoblot analysis of the lysates prepared from the transfectants showed that GFP-wt mortalin and GFP-mortalinDp53BD proteins were expressed at similar levels ( Figure 4A (B) HeLa1/vec and HeLa1/p53i cells were exposed to hydroxyurea (HU) for 72 h. Cells before HU treatment and HUtreated cells were immunostained for centrosomes using anti-g-tubulin antibody, and the number of centrosomes per cell was determined and shown in the graph as average7standard error from three experiments. >300 cells were examined for each experiment. (C) HeLa1 cells were transiently transfected with either a green fluorescent protein (GFP)-vector or a plasmid encoding GFP-mortalin. The transfectants were immunostained with anti-g-tubulin antibody, and counterstained for DNA with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI). The insets show the magnified images of the indicated areas. The arrows point to the positions of centrosomes. Scale bar, 10 mm. (D and E) The GFP-vector-and GFP-mortalin-transfected cells described above were exposed to HU for 72 h, immunostained with anti-g-tubulin antibody and counterstained for DNA with DAPI. The number of centrosomes per cell in GFP-positive cells was determined, and shown in the graph (D) as average7standard error from three experiments. In each experiment, >200 cells were examined. The representative immunostaining images of GFP-vector-and GFP-mortalin-transfected cells after HU treatment are shown in (E). Panels 1-3 show the magnified images of the indicated areas. Scale bar, 10 mm.
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Z Ma et al (Figure 4A(b) , left panel). Green fluorescent protein-wt mortalin, but not GFP-mortalinDp53BD, was coimmunoprecipitated with anti-p53 antibody. Thus, exogenously introduced GFP-mortalin can physically associate with endogenous p53, and mortalin deleted for the a.a. 253-282 failed to bind to p53 as shown previously (Kaul et al., 2001 ).
We next examined whether the GFP-mortalinDp53BD mutant localizes to centrosomes by immunostaining the GFP-mortalinDp53BD-transfectants with anti-g-tubulin antibody. We found that the deletion of the p53-binding region (a.a. 253-282) had no effect on centrosomal localization of mortalin, hence GFPmortalinDp53BD localized to centrosomes ( Figure 4B ). The p53-binding mutant mortalin localizes to centrosomes. Cells transfected with GFPmortalinDp53BD were immunostained with anti-g-tubulin antibody (red), counterstained for DNA with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI) (blue) and centrosomal localization of the GFP-mortalinDp53BD mutant was examined. Green fluorescent protein-mortalinDp53BD mutant binds to unduplicated (panels a-c) and duplicated (panels d-f) centrosomes in a manner similar to wild-type mortalin. The arrows point to the positions of centrosomes. The insets show the magnified images of the areas indicated by arrows. Scale bar, 10 mm. (C) The GFP-vector-, GFP-mortalin-and GFP-mortalinDp53BD mutant-transfected cells were exposed to hydroxyurea for 72 h, immunostained with anti-g-tubulin antibody and counterstained for DNA with DAPI. The number of centrosomes per cell in GFP-positive cells was determined, and shown in the graph as average7standard error from three experiments. In each experiment, >200 cells were examined.
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Further analysis revealed that the kinetics of centrosomal association of GFP-mortalinDp53BD was identical to wt mortalin, localizing to unduplicated centrosomes in mid-late G1, continuing to localize at centrosomes during S and G2, and dissociating from centrosomes during mitosis (data not shown). Thus, centrosomal localization of mortalin is independent of its p53-binding activity.
We next tested whether loss of the p53-binding activity affects the centrosome duplication regulatory function of mortalin. The GFP-, GFP-wt mortalin-and GFP-mortalinDp53BD-transfectants (at 36 h post-transfection) were exposed to HU for 72 h, and the frequency of centrosome re-duplication (generation of amplified centrosomes) during HU-induced arrest was determined ( Figure 4C ). Expression of GFP-wt mortalin led to a high frequency of centrosome re-duplication (B40% of cells with X3 centrosomes). In contrast, expression of mortalinDp53BD mutant resulted in only a small increase in the frequency of centrosome amplification at a similar degree with the control vector-transfected cells (B10%). Thus, mortalinDp53BD mutant no longer possesses the ability to override the p53-dependent suppression of centrosome re-duplication during HUinduced arrest, indicating that the p53-binding activity is critical for mortalin to override the p53-dependent suppression of centrosome duplication, and to drive centrosome duplication.
Mortalin overexpression does not affect the transactivation function of p53 in HeLa1 cells
To further delineate the molecular mechanism underlying the regulation of centrosome duplication by physical interaction between mortalin and p53, we explored how mortalin would affect the properties and activities of p53. It has previously been reported that mortalin inhibits the transactivation function of p53 through physical interaction and consequential cytoplasmic sequestration of p53 (Wadhwa et al., 1998 . As it is known that p53 controls centrosome duplication in part via transactivation of p21 Waf1/Cip1 (p21) cyclin-dependent kinase (CDK) inhibitor (Tarapore et al., 2001a), it is possible that mortalin controls centrosome duplication through modulating the transactivation function of p53. To test this, we transiently transfected FLAG epitope-tagged wt mortalin and mortalinDp53BD mutant into HeLa1 cells. As a control, a FLAG vector was transfected. The transfection efficiency of HeLa1 cells is high, and >70% of cells can be routinely transfected. The lysates were prepared from the transfectants at 36 h post-transfection, and subjected to immunoblot analysis using anti-FLAG, anti-p53, anti-p21 and anti-b-tubulin (loading control) antibodies ( Figure 5A ). Similar levels of FLAG-wt mortalin and FLAG-mortalinDp53BD mutant were expressed (top panel). The levels of p53 were similar between FLAG-wt mortalin-and FLAG-mortalinDp53BD-transfected cells (second panel), hence expression of either wt mortalin or mortalinDp53BD mutant does not affect the protein stability of p53. HeLa1 cells were co-transfected with FLAG and green fluorescent protein (GFP)-vectors, FLAG-vector and GFP-p53, FLAG-wt mortalin and GFP-p53, and FLAG-mortalinDp53BD and GFP-p53. The lysates prepared from the transfectants were subjected to immunoblot analysis using anti-FLAG (top panel), anti-GFP (second panel), anti-p21 (third panel) and anti-b-tubulin (loading control, fourth panel) antibodies. The cell lysates were also subjected to immunoprecipitation using anti-FLAG antibody. The immunoprecipitates were then immunoblotted with anti-FLAG (fifth panel) or anti-GFP (bottom panel) antibodies. (C) HeLa1 cells co-transfected with FLAG-vector, FLAG-wt mortalin or FLAG-mortalinDp53BD along with GFP-p53 were immunostained with anti-FLAG (red, panels a-c), and counterstained for DNA with 4 0 ,6 0 -diamidino-2-phenylindole (blue, panels g-i). The autofluorescent images of GFP are shown in panels d-f (green). Scale bar, 10 mm.
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Surprisingly, contrary to the previous studies, there was no noticeable difference in the levels of p21 among all the transfectants (third panel). Thus, in HeLa1 cells, mortalin does not appear to inhibit the transactivation function of p53. Although the previous studies have also indicated that mortalin inhibits the transactivation function of p53 via cytoplasmic sequestration of p53 (Wadhwa et al., 1998 , we examined whether forced expression of mortalin induces the cytoplasmic sequestration of p53. As the endogenous level of p53 is very low to immunocytochemically determine the changes in the nuclear and cytoplasmic localization, we decided to introduce GFP-tagged p53. HeLa1 cells were transiently co-transfected with GFP-p53 together with either FLAG-wt mortalin or FLAG-mortalinDp53BD. As controls, cells were co-transfected with FLAG-and GFP-vectors as well as FLAG-vector and GFP-p53. The cell lysates prepared from the transfectants at 36 h post-transfection were subjected to immunoblot analysis using anti-FLAG, anti-GFP, anti-p21 and anti-b-tubulin (loading control) antibodies ( Figure 5B , top four panels). The equivalent levels of FLAG-wt mortalin and FLAG-mortalinDp53BD were detected in the cells transfected with the plasmids encoding these proteins (top panel, lanes 3 and 4). Similar levels of GFP-p53 proteins were also expressed in the transfectants (second panels, lanes 2-4). As expected from the result shown in Figure 5A , p21 was upregulated at similar levels in all of the GFP-p53-transfected cells regardless of co-transfection of the control vector, wt mortalin or mortalinDp53BD (third panel, lanes 2-4 compared with the control in lane 1). Thus, expression of wt mortalin does not negatively affect the transactivation activity of the transfected GFP-p53 (as well as endogenous p53) in HeLa1 cells. The cell lysates were also subjected to immunoprecipitation using anti-FLAG antibody, and the immunoprecipitates were immunoblotted with anti-GFP (for transfected p53) as well as anti-FLAG (for transfected wt and mutant mortalins) antibodies ( Figure 5B , bottom two panels). Similar levels of wt mortalin and mortalinDp53BD were immunoprecipitated (fifth panel). Expectedly, GFP-p53 was coimmunoprecipitaed only with wt mortalin, but not with mortalinDp53BD mutant (bottom panel). Thus, GFPmoiety does not affect the mortalin-binding activity of p53.
To test whether overexpression of mortalin results in cytoplasmic sequestration of p53, the transfectants were immunostained with anti-FLAG antibody ( Figure 5C ). Although both wt mortalin and mortalinDp53BD mutant were distributed in both the nucleus and cytoplasm, wt mortalin were found more in the cytoplasm (panel b), whereas mortalinDp53BD were found more in the nucleus (panel c). However, in both wt mortalin-and mortalinDp53BD-transfected cells, GFP-p53 remained mostly in the nucleus (panels e and f), indicating that mortalin overexpression does not appear to effectively induce cytoplasmic sequestration of p53 in HeLa1 cells.
Mortalin drives centrosome duplication through blocking the centrosomal localization of p53
The physical interaction between mortalin and p53 affect neither the protein stability nor transactivation function of p53 in HeLa1 cells. As a number of studies have shown that p53 is present at centrosomes (Blair Zajdel and Blair, 1988; Brown et al., 1994; Morris et al., 2000; Ciciarello et al., 2001; Tarapore et al., 2001b) , we next examined whether mortalin affects the centrosomal localization of p53. The mortalin-binding region of mouse p53 has been previously identified to a.a. 312-352 (a.a. 314-355 of human p53) . We constructed a plasmid encoding FLAG epitope-tagged p53 deleted for the mortalin-binding sequence (FLAGp53DmotBD). The FLAG-tagged wt p53 (FLAG-wt p53) and FLAG-p53DmotBD were transfected into HeLa1 cells along with either HA-tagged wt mortalin or a HA-vector control at 1:15 molar ratio. Under this transfection protocol, virtually all the FLAG-positive cells were HA-positive, which was confirmed by co-immunostaining with anti-FLAG and anti-HA antibodies (data not shown). At 36 h post-transfection, the transfectants were immunostained using anti-FLAG and anti-g-tubulin antibodies ( Figure 6A ). As previously shown (Tarapore et al., 2001b) , the transfected FLAGwt p53 localizes to centrosomes ( Figure 6A , panels a-c). However, when wt mortalin was co-expressed, the frequency of centrosome localization of FLAG-wt p53 was substantially reduced ( Figure 6A , panels d-f). FLAG-p53DmotBD mutant localizes to centrosomes similar to FLAG-wt p53 (panels g-i). Importantly, when wt mortalin was co-expressed, the FLAG-p53DMotBD mutant remained at centrosomes. The frequencies of the centrosomal localization of FLAG-wt p53 and FLAGp53DMotBD mutant in the presence or absence of exogenously introduced mortalin are shown in Figure 6B . As FLAG-p53DmotBD lacks the region responsible for mortalin-binding, these results strongly suggest that mortalin-binding reduces the centrosomebinding affinity of p53.
To test whether physical interaction of mortalin and p53 and the consequential dissociation of p53 from centrosomes were involved in the regulation of centrosome duplication, we decided to examine the effects of co-expression of either wt p53 or p53DmotBD mutant with mortalin on centrosome duplication. We have previously shown that the transactivation of inactive p53 mutant R175H (arginine residue at a.a. 175, a known hot spot mutation found in human cancer (Hollstein et al., 1991) , is replaced to histidine) no longer possesses the ability to localize to centrosomes (Tarapore et al., 2001b) . Thus, R175H can serve as an appropriate negative control for differentiating the transactivation and centrosome-binding activities of p53 in the regulation of centrosome duplication. We first characterized wt p53, p53DmotBD and R175H for their mortalin-binding and transactivation activities. To this end, HeLa1 cells were transfected with FLAGvector, FLAG-wt p53, FLAG-p53DmotBD or FLAG-R175H. The lysates prepared from the transfectants at 36 h post-transfection were subjected to immunoblot analysis using anti-FLAG, anti-p21 and anti-b-tubulin (loading control) antibodies (Figure 7a , bottom three panels). The level of FLAG-wt p53 was lower than those of R175H and FLAG-p53DmotBD mutants (second panel), which was expected from the unstable nature of wt p53. The immunoblot analysis of p21 showed that p21 was highly upregulated in the FLAG-wt p53-transfected cells (lane 2, third panel). As p21 is expressed at a basal level in a p53-dependent manner (Mussman et al., 2000) , a low level of p21 expression was detected in the vector transfectants (lane 1, third panel). In the R175H-transfected cells, there was a noticeable reduction of the p21 level compared with the vectortransfected cells (lane 3), which was expected from the fact that R175H mutant inactivates the transactivation function of endogenous wt p53 through sequestration (Crook et al., 1994) . In contrast, in the p53DmotBD transfectants, the p21 level was no more than the vectortransfected cells (lane 4), indicating that p53DmotBD lost transactivation function, but was unable to inactivate the transactivation function of endogenous wt p53. The lysates were also immunoprecipitated with anti-FLAG antibody, and the immunoprecipitates were immunoblotted with anti-mortalin antibody ( Figure 7A, top panel) . Endogenous mortalin was coimmunoprecipitated with both FLAG-wt p53 (lane 3) and FLAG-R175H (lane 4), but not with FLAGp53DmotBD (lane 5), demonstrating that FLAGp53DmotBD lacks ability to bind to mortalin, whereas FLAG-R175H retains the mortalin-binding activity. The mortalin-binding, transactivation and centrosomebinding activities of wt p53, p53DmotBD and R175H are summarized in Figure 7B .
We next co-transfected FLAG-wt p53, FLAGp53DmotBD or FLAG-R175H along with GFP-wt mortalin into HeLa1 cells that had been already arrested by HU treatment for 24 h. As a control, FLAG-vector was transfected. For a control for the GFP-wt mortalin, GFP-vector was co-transfected. It should be noted here that it is necessary to arrest the cells by exposure to HU before transfection in this experiment, because overexpression of wt p53 is cytotoxic and induces cell death especially when cells are cycling. We have found that when cells are arrested by HU, cells can tolerate the introduction of high levels of wt 53, and thus cells remain viable. In addition, by arresting the cells by HU before transfection, we can avoid any interference from the cell cycle alteration resulting from overexpression of wt p53 -wt p53 is known to induce G1 as well as G2 arrest if not inducing cell death (Agarwal et al., 1995; Stewart et al., 1995) . The cells were continued to be exposed to HU after transfection for additional 36 h, immunostained for centrosomes, and the number of centrosomes per cell was determined ( Figure 7C ). Among the control cells, B8% of cells had amplified centrosomes (column 1). Overexpression of mortalin alone overrides the p53-dependent suppression of centrosome re-duplication (B22%, column 5). The introduction of R175H mutant allowed centrosomes to undergo re-duplication (B18%, column 3), likely owing to the physical sequestration and inhibition of endogenous wt p53. When mortalin was co-transfected with R175H mutant, centrosome re-duplication was further promoted (B35%, column 7). In cells transfected with wt p53, centrosome re-duplication remained inhibited (B5%, column 2). When mortalin was co-transfected with wt p53, there was a small increase in the frequency of centrosome re-duplication (B10%, column 6), which was likely due to the presence of excess p53 (transfected and endogenous p53) making mortalin not to be able to completely override the p53-dependent suppression of centrosome re-duplication. In cells transfected with p53DmotBD mutant, centrosome re-duplication remained inhibited (B3%, column 4). Importantly, when mortalin was co-transfected with p53DmotBD, Mortalin modulates centrosomal association of p53 via physical interaction. (A) HeLa1 cells were co-transfected with either FLAG-wild-type (wt) p53 or FLAG-p53DmotBD with either HA-wt mortalin or HA-vector at 1:15 molar ratio. The transfectants were co-immunostained with anti-FLAG (red) and anti-gtubulin (green) antibodies. Cells were also stained for DNA with 4 0 ,6 0 -diamidino-2-phenylindole (blue). The arrows point to the positions of centrosomes. The insets show the magnified images of the areas indicated by arrows. Scale bar, 10 mm. (B) Among the transfected cells described in (A), FLAG-positive cells were examined for the frequencies of colocalization of the anti-FLAG antibody-reactive dot signals and anti-g-tubulin-reactive dot signals (centrosomes), and the results were shown as average7standard error from three experiments. In each experiment, >200 cells were examined.
Regulation of centrosome duplication
Z Ma et al centrosome re-duplication remained inhibited (B5%, column 8). As the p53DmotBD mutant lacks the transactivation function, but is able to continuously associate with centrosomes owing to its inability to interact with mortalin. These results demonstrate that p53 negatively controls centrosome duplication via directly associating with centrosomes in a transactivation function-independent manner, and mortalin is involved in the regulation of centrosome duplication via modulating the centrosome-binding activity of p53.
Discussion
Through the mass spectrometric characterization of unduplicated and duplicated centrosomes, we identified mortalin as proteins that are preferentially associated with duplicated centrosomes. Further characterization of centrosomal association of mortalin revealed that mortalin starts to localize at centrosomes in mid-late G1 phase of the cell cycle, remains associated with centrosomes during S and G2 phase, and dissociates from centrosomes during mitosis. As mortalin is present at similar levels throughout the cell cycle, the cell cycle (as well as centrosome duplication cycle) specific localization of mortalin is likely mediated by post-translational modifications such as phosphorylation. Indeed, it has been shown that mortalin is phosphorylated on multiple sites (Hadari et al., 1997; Z Ma and M Kanai, unpublished observation) . Alternatively, mortalin may require other protein(s) to localize to centrosomes, and such protein(s) may be expressed or post-translationally modified in a cell cycle-dependent manner. We further Regulation of centrosome duplication Z Ma et al found that mortalin is involved in the regulation of centrosome duplication. When DNA synthesis is blocked by exposure to DNA synthesis, inhibitors such as aphidicolin (Aph) and HU cells continue to reduplicate centrosomes without DNA synthesis, resulting in the generation of abnormally amplified centrosomes. However, this occurs preferentially in the absence of p53. In the presence of p53, both DNA synthesis and centrosome re-duplication become halted. In addition, it is known that centrosome re-duplication requires relatively uncontrolled activation of CDK2 (Kawamura et al. 2004) . In rodent cells, which show rather promiscuous activation of CDK2/cyclin E (or cyclin A) when p53 is either functionally inactivated or lost, centrosomes continue to re-duplicate during HU as well as Aph-induced arrest (Tarapore et al., 2001a) . In contrast, in human cells, CDK2 activation is under a higher order of regulation even in the absence of p53, hence the presence of higher levels of cyclin E (and possibly cyclin A) is required for centrosomes to undergo re-duplication during the HU-induced arrest (Kawamura et al., 2004) . HeLa1 cells used in this study retain functional p53, yet CDK2 activation is less strictly controlled than normal human cells when expression of p53 is silenced, making HeLa1 cells suitable for studying the role of p53 in the regulation of centrosome duplication in human cells. When mortalin is transiently transfected in HeLa1 cells, centrosomes undergo re-duplication during HU-induced arrest. Thus, overexpression of mortalin can override the p53-dependent suppression of centrosome duplication, indicating the functional interaction between mortalin and p53 in the regulation of centrosome duplication. It has previously been shown that mortalin physically interact with p53, which results in cytoplasmic sequestration of p53, hence inactivation of p53's transactivation function (Wadhwa et al., 1998) . We thus initially thought that inhibition of p53's transactivation function was the underlying mechanism for mortalin to override the p53-dependent suppression of centrosome duplication. However, we failed to detect inactivation of p53's transactivation function by mortalin overexpression in HeLa1 cells. Although subcellular localization of p53 was slightly shifted to the cytoplasm by mortalin overexpression, expression levels of the transactivation target proteins such as p21 and MDM2 were similar to the control cells even when cells were challenged with genotoxic stress (data not shown). A possible explanation can be readily drawn for the discrepancy between the previous studies and our present study. As the cytoplasmic sequestration of p53 is the mechanism of how mortalin inactivates p53's transactivation function, it is clear that such inactivation is highly dose (level of introduced mortalin) dependent. As the efficiency of expression of exogenously introduced genes is different from cell lines to cell lines, p53 can be inactivated more efficiently by exogenously introduced mortalin more effectively in some cell lines than in other cell lines. In HeLa1 cells, expression level of exogenously introduced mortalin may not be sufficient to inactivate the transactivation function of endogenous p53. Indeed, as mentioned above, there was a slight shift of nuclear to cytoplasmic localization of p53 by introduction of mortalin in HeLa1 cells, supporting this possibility. Nevertheless, failure to inactivate p53's transactivation function by introduction of mortalin in HeLa1 cells has provided us an opportunity to differentiate the transactivation and centrosome-binding activities of p53 in the regulation of centrosome duplication. Using this experimental system, we could identify the transactivation function-independent regulation of centrosome duplication by p53. A number of studies have shown centrosomal association of p53 (Blair Zajdel and Blair, 1988; Brown et al., 1994; Morris et al., 2000; Ciciarello et al., 2001; Tarapore et al., 2001b) , although the role of centrosomally localized p53 in the regulation of centrosome duplication has been unclear. When we examined the potential effect of mortalin on centrosomal localization of p53, we found that mortalin promoted dissociation of p53 from centrosomes. We further found that dissociation of p53 from centrosomes requires direct physical interaction between mortalin and p53. At present, we do not know the molecular nature of how mortalin affects the centrosomal association of p53. Mortalin may prevent cytoplasmic p53 to associate with centrosomes via sequestering p53 to other cellular compartments. If this is the case, mortalin-p53 complex should no longer possess the centrosome-binding activity. Alternatively, p53 may lose the centrosomebinding affinity when bound by mortalin, in which case the physical interaction between mortalin and p53 can occur at centrosomes as well as in the cytoplasm. Because the centrosome-binding region of mortalin as well as potential centrosomal proteins that mortalin and/or p53 have not yet been identified, which is currently pursued in our laboratory, we are unable to test these possibilities at present. The observation that mortalin promotes dissociation of p53 from centrosomes provided us an opportunity to directly address the role of centrosomally localized p53 in the regulation of centrosome duplication. We found that p53 deleted for mortalin binding sequence (a.a. 314-355) (p53DmotBD) was no longer transactivation active, and remained associated with centrosomes even when mortalin was overexpressed. We have previously shown that the transactivation activity-negative p53 missense mutant R175H lacks the ability to bind to centrosomes (Tarapore et al. 2001b) . Although mortalin overexpression override the p53-dependent suppression of centrosome re-duplication during the HU-induced arrest, the presence of excess wt p53 (exogenously introduced by transfection) lessens the effect of mortalin overexpression on centrosome re-duplication, hence centrosome re-duplication is considerably inhibited. Co-expression of R175H mutant (centrosome-binding negative, transactivation negative) showed no effect on mortalin-mediated release of centrosome re-duplication inhibition during HU-induced arrest, hence centrosomes continue to re-duplicate. In contrast, co-expression of p53DMotBD (centrosome-binding positive, transactivation negative) resulted in complete inhibition of centrosome re-duplication driven by mortalin overexpression.
These observations strongly indicate that p53 negatively controls centrosome duplication via binding to centrosomes, and dissociation of p53 from centrosomes may be critical for centrosomes to initiate duplication, which is catalysed by physical interaction with mortalin. We believe that this is the first demonstration of the role of centrosomally localized p53 in the regulation of centrosome duplication. The major question remained to be answered is the molecular mechanism underlying the direct regulation of centrosome duplication by centrosomally localized p53. It is likely that p53 modulates the activities of centrosomal protein(s) that play critical roles in the initiation of centrosome duplication through direct physical interaction. In this context, mortalin promotes dissociation of the protein complex between p53 and those centrosomal proteins through physical interaction, leading to initiation of centrosome duplication.
Materials and methods
Cells and transfection
HeLa-1 cell line, a clonal derivative of HeLa cervical carcinoma cells, was derived from the single cell cloning of HeLa cells. A number of subcloned cells were tested for expression of p53, p53-dependent checkpoint function, centrosome number and coordination of the centrosome and cell cycles. One cell line (HeLa-1) was found to behave similar to primary normal human cells in all the phenotypes described above. We further found that the transcripts of E6 and E7 human papilloma virus proteins were undetectable in HeLa-1 cells by reverse transcription-polymerase chain reaction, hence expression of these viral proteins are likely silenced at a transcriptional level in these cells. HeLa-1 cells were maintained in complete medium (Dulbecco's modified Eagles's medium supplemented with 10% fetal bovine serum, penicillin (100 Us/ml) and streptomycin (100 mg/ml)) in an atmosphere containing 5% CO 2 . Transfections were performed using either FuGENE 6 transfection reagent (Roche Applied Sciences, Indianapolis, IN, USA) or Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The transfection efficiency of HeLa-1 cells is >70% using this reagent.
Antibodies
The antibodies used in this study were as follows: antimortalin monoclonal antibody (clone JG-1, Affinity Bioreagents, Golden, CO, USA), anti-mortalin polyclonal antibody (clone H-155, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-g-tubulin monoclonal antibody (clone GTU-88, Sigma-Aldrich, Milwaukee, WI, USA), anti-Bcl-xL polyclonal antibody (clone L-19, Santa Cruz), anti-p53 monoclonal antibody (clone DO-1, Santa Cruz), anti-GFP monoclonal antibody (clones 7.1. plus 13.1, Roche), anti-b-tubulin monoclonal antibody (clone Tub. 2.1, Sigma), anti-FLAG monoclonal antibody (M2, Sigma) and anti-p21 monoclonal antibody (F-5, Santa Cruz). Anti-g-tubulin polyclonal antibody was generated in our laboratory.
Centrosome isolation
Centrosomes were prepared from HeLa-1 cells as described previously . Briefly, cytoplasmic extracts prepared by osmotic lysis and removal of nucleus were subjected to discontinuous sucrose gradient (500 ml of 70%, 300 ml of 50% and 300 ml of 40% sucrose solutions) centrifugation. The fractions were collected from the bottom.
Two-dimensional gel electrophoresis
The centrosome enriched fractions were diluted with 40 ml of PIPES buffer (10 mM PIPES (pH 7.2)), and applied to the anode side of the isoelectric focusing rod gels (diameter 1.5 mm) containing 4% acrylamide, 0.24% bisacrylamide, 9 M urea, a total of 2% w/v carrier ampholytes (pH 5/7: pH 3/10 ¼ 2:1) and focused in a vertical isoelectric focusing chamber. The gels were then equilibrated for 5 min in a buffer (125 mM Tris (pH 6.8), 2% sodium dodecyl sulfate (SDS), 10% glycerol, 9 mM DTT, 0.5 mg/ml bromophenol blue), and immediately applied to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Mass spectrometry
The 2D gel spots were excised, washed in 25 mM ammonium bicarbonate/50% acetonitrile, and then 100% acetonitrile, freeze-dried, swollen in the digestion buffer (0.01 mg/ml modified porcine trypsin (Promega, Madison, WI, USA), 25 mM ammonium bicarbonate (pH 8.0)), and incubated overnight at 371C. Peptides were extracted by three changes of 50% acetonitrile/5% trifluoroacetic acid (TFA) and desiccated by vacuum centrifugation. The dried peptide mixture was dissolved in 20 ml of 3% TFA, desalted by binding to C18 resin (ZipTip, Millipore, Bedford, MA, USA), and eluted with 50% acetonitrile containing a-cyano-4 hydroxy trans-cinnamic acid onto a Teflon sample stage. Mass spectra were recorded using an ABI QStar Pulsar QqTOF mass spectrometer with oMALDI source (PE Biosystems, Framingham, MA, USA) and calibrated using tryptic autodigestion peaks as internal standards. The protein was identified by peptide fingerprinting, searching against the NCBInr.62998 database, and confirmed by MS/MS sequencing of at least one and usually >2 tryptic peptides. MS-Fit and MS-Tag software were used for mass spectral analyses (http://prospector.ucsf.edu/).
Immunoblot analysis and immunoprecipitation
For immunoblot analysis, cells were lysed in SDS/1% Nonidet P-40 (NP-40) lysis buffer (1% SDS, NP-40, 50 mM Tris (pH 8.0), 150 mM NaCl, 4 mM Pefabloc SC (Boerhinger Mannheim, Indianapolis, IN, USA), 2 mg/ml leupeptin, 2 mg/ml aprotinin). The lysates were briefly sonicated, boiled for 5 min and then cleared by a 10-min centrifugation at 20 000 g at 41C. Protein concentrations of the lysates were determined using the BCA protein assay reagent (Pierce Biotechnology, Rockford, IL, USA). The lysates were further denatured at 951C for 5 min in sample buffer (2% SDS, 10% glycerol, 60 mM Tris (pH 6.8), 5% b-mercaptoethanol, 0.01% bromophenol blue), resolved by SDS-PAGE, and transferred to Immobilon-P sheets (Milipore Corp.). The blots were incubated in blocking buffer (5% (wt/vol) nonfat dry milk in Tris-buffered saline þ 0.2% Tween 20 (TBS-T)) for 1 h at room temperature and then primary antibody for 16 h at 41C. The blots were then rinsed in TBS-T and incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The blots were rinsed in TBS-T, and the antibody-antigen complex was visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
For immunoprecipitation, cells were lysed in NP-40 lysis buffer (1% NP-40, 50 mM Tris (pH 8.0), 150 mM NaCl, 2 mg/ml leupeptin, 2 mg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 5 mM NaF, 100 mM Na 3 VO 4 ). The lysates were precleared by incubation with protein G or A agarose beads for 1 h at 41C. The lysates were then incubated with antibody on a rotating wheel for 6 h at 41C. Protein G or A agarose beads were then added and the mixtures were further incubated on a rotating wheel for 2 h at 41C. The agarose beads were pelleted and washed three times in lysis buffer. Antibody-antigen complexes bound to the beads were eluted in sample buffer by boiling, resolved by SDS-PAGE, and analysed by immunoblotting with appropriate antibodies.
Indirect immunofluorescence
Cells grown on coverslips were washed in phosphate-buffered saline (PBS), and fixed with either 10% formalin/10% methanol for 20 min at room temperature or methanol/acetone for 15 min at À201C. In some cases, cells were subjected to brief extraction (30 s) with extraction buffer (0.1% Triton X-100 in PBS before fixation. The cells were incubated with blocking solution (10% normal goat serum in PBS) for 1 h. The cells were then probed with primary antibodies for 1 h, and antibody-antigen complexes were detected with either Alexa Fluor 488-or Alexa Fluor 594-conjugated goat secondary antibody (Molecular Probes, Eugene, OR, USA) by incubation for 1 h at room temperature. The cells were washed three times with PBS after each incubation, and then counterstained for DNA with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI). Cells were examined under a fluorescence microscope (Nikon Microphot-FX) using a Â 60 objective lens. The fluorescence images were captured with SPOT CCD camera (Diagnostic Instruments Inc., Sterling Heights, MI, USA).
For analysis of 5-bromodeoxyuridine (BrdU)-incorporation of synchronized cells, cells were first serum-starved for 24 h, followed by serum-stimulation in the presence of BrdU using the BrdU labeling kit (Roche), according to the manufacturer's instructions. At the end of BrdU labeling, cells were fixed in 70% methanol for 20 min at -201C, followed by treatment with 4 M HCl for 3 min at room temperature. Cells were then incubated in the blocking buffer for 1 h at room temperature, and immunostained with anti-BrdU monoclonal antibody.
